Health Economics›Non-small cell lung cancer›Advanced or metastatic disease EGFR p.T790M mutation

Advanced or metastatic disease EGFR p.T790M mutation

Non-small cell lung cancer · 4 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Osimertinib monotherapy Variant #01	EGFR	R 77 777	28d	16.6 mo	38.1 mo	19	R 1 477 762 PFS proxy	13
Docetaxel and Bevacizumab Variant #01	EGFR	R 30 693	21d	~8.2 mo	—	~12	~R 368 311 PFS proxy · indirect	4
Cisplatin and Pemetrexed Variant #01	EGFR	R 1 088	21d	5.5 mo	22.5 mo	8	R 8 701 PFS proxy	20
Carboplatin and Pemetrexed N/A - secondary systemic drug	EGFR	R 52	21d	5.6 mo	22.5 mo	9	R 469 PFS proxy	18

4 of 4 regimens shown